Contexte : L'obésité est considérée par l'OMS comme une « épidémie » mondiale en raison de l'essor de sa prévalence et de ses conséquences sur la santé. Chez les patientes enceintes, son impact semble tout aussi préoccupant et sa prévalence en France atteint actuellement 10%. Certaines complications de l'obésité chez la femme enceinte ont été peu étudiées et notamment le lien particulier avec la macrosomie fœtale.Objectifs : Mieux appréhender la prise en charge des patientes enceintes obèses et de certaines complications qui en découlent.Méthodes : Trois séries de données différentes ont servi pour répondre à différentes questions sur la thématique de l'obésité et de la macrosomie. 1) Une évaluation de la faisabilité et de la qualité d'une échographie obstétricale du 2ème trimestre chez les patientes obèses a été réalisée via une étude mono centrique avec recueil prospectif des données. 2) Une étude des facteurs de risques de complications maternelles en cas d'accouchement d'un enfant macrosome, indépendamment de l'obésité maternelle et du poids de naissance de l'enfant a été menée sous la forme d'une étude prospective de cohorte d'enfant de plus de 4000g dans deux maternités d'Ile de France. 3) Enfin, une comparaison de la relation entre les complications maternelles de la grossesse et /ou néonatales et l'obésité a été menée entre la France (4 maternités de type III) et le Québec (données issues d'une étude randomisée dans toute la province) entre 2009 et 2011 via une étude comparative de deux échantillons transversaux de femmes enceintes (26 973 accouchements en France et 83 545 accouchements au Québec). Résultats : 1) Une échographie du deuxième trimestre de la grossesse chez une population obèse est possible, avec un taux de réussite en une fois de 70,4 %, (versus 82% ; p=0,08). Les facteurs d'amélioration de ce taux étaient : passer plus de temps lors de l'échographie (p=0,03), déplacer le fœtus de sorte que son dos soit en position latérale ou postérieure (p=0,01), et échographie réalisée par des échographistes expérimentés (p=0,03). Néanmoins, la qualité des images reste significativement moins bonne dans la population obèse (p=0,001). 2) La survenue de complications maternelles lors de la tentative d'accouchement vaginal d'un enfant de plus de 4000 g est de 6%. Les facteurs de risque de complications maternelles, outre le poids de naissance de l'enfant (p=0,004, Risque attribuable (RA)=10%), sont l'origine asiatique de la mère (p=0,04 ; RA=3%), une durée longue du travail (>10h) (p=0,02 ; RA=12%), et une césarienne au cours du travail (p=0,004 ; RA=17%). Les patientes multipares ayant déjà accouché par voie vaginale d'un enfant macrosome avaient un risque diminué de complications maternelles (p=0,03). 3) La prévalence de l'obésité était de 9,1% en France et 16,8% au Québec (p<0,001). L'obésité était associée de manière statistiquement significative (p<0,0001), à la fois en France et au Québec, à un risque accru de diabète gestationnel, de troubles hypertensifs de la grossesse, de prééclampsie, de mort fœtale in utero, d'accouchement par césarienne et de macrosomie. L'association était différente en France et au Québec (p interaction <0,005), pour la survenue du diabète gestationnel, de complications hypertensives de la grossesse et pour la macrosomie, avec une augmentation plus importante des complications avec l'IMC au Québec par rapport à la France.Conclusion : La compréhension de certaines complications inhérentes à l'obésité (complications médicales de la grossesse, faisabilité et qualité du dépistage échographique, complications obstétricales) est améliorée par les résultats de cette thèse. / Background: According to WHO, obesity is considered as an "epidemic" condition due to the global growth of its prevalence and its impact on patient health. For pregnant patients, its impact seems equally worrying and its prevalence is now reaching 10% in France. Some complications of obesity in pregnant women have been little studied and particularly the special link with fetal macrosomia.Objectives: To better understand care and obstetric outcome of obese pregnant patients as well as some of their complications such as fetal macrosomia.Methods: Three different sets of data were used to deal with questions regarding obesity and macrosomia. 1) Assessment of feasibility and quality of second trimester ultrasound scan in obese patients was performed through a mono centric case-control study with prospective data collection. 2) A study of risk factors for maternal complications in case of the delivery of a macrosomic child, regardless of maternal obesity and child's birth weight, was conducted as a prospective cohort study including children with birthweight above 4000g in two “Ile de France” maternity wards. 3) Finally, a comparison of the relationship between maternal and/or neonatal complications of pregnancy and obesity was conducted in France (4 type III maternity wards) and in Quebec (data from a randomized study throughout the province) between 2009 and 2011 through a comparative study of two cross-sectional samples of pregnant women (26,973 births in France and 83,545 births in Quebec).Results: 1) Second trimester ultrasound scan in obese pregnant women is feasible, with a success rate of 70.4% (versus 82%; p=0.08). Factors of improvement were: to spend more time at ultrasound (p=0.03), to move the fetus so that its back is in lateral or posterior position (p=0.01) and when ultrasound was performed by experienced sonographers (p=0.03). However, the quality of the image remains significantly lower in the obese population (p=0.001). 2) The occurrence of maternal complications, when attempting vaginal birth of a child of more than 4000g, was 6%. Beyond childbirth weight (p=0.004, attributable risk (AR) = 10%), the risk factors of maternal complications were Asian ethnicity (p=0.04; AR=3%), prolonged labor (> 10h) (p=0.02; AR=12%), and caesarean section during labor (p=0.004; AR=17%). Multiparous women with a previous vaginal delivery of a macrosomic child had a lower risk of maternal complications (p=0.03). 3) The prevalence of obesity was 9.1% in France and 16.8% in Quebec (p <0.001). Obesity was significantly (p <0.0001) associated with, both in France and in Quebec, an increased risk of gestational diabetes, hypertensive disorders of pregnancy, preeclampsia, stillbirth, cesarean delivery and macrosomia. The strength of the association was different in France and Quebec (p of interaction <0.005) for the occurrence of gestational diabetes, hypertensive complications of pregnancy and macrosomia, with a larger increase in complications with body mass index in Quebec compared to France.Conclusion: Understanding some inherent complications of obesity (medical complications of pregnancy, feasibility and quality of ultrasound screening, obstetric complications) is enhanced by the result of this work.

Background: Gestational Diabetes Mellitus (GDM) has been linked with later metabolic abnormalities in offspring due to subsequent overweight and obesity. In Sub-Saharan Africa, there is a paucity of data on the outcomes of children exposed to GDM in utero. Aims: The primary aim of this sub-study was to investigate the prevalence of overweight and obesity in 5 and 6-year-old children from GDM complicated pregnancies and macrosomia at birth in the same cohort. The secondary aim was to identify risk factors associated with overweight and obesity in these 5 and 6-year-old children. Outcome measures: The main outcome was the prevalence of overweight and obesity in these children as measured by their age-specific body mass index (BMI) and Z-scores. Additionally, the association between other risk factors, overweight and obesity was investigated. Methods: A cross-sectional sub-study design was employed nested within a larger study that is investigating the progression to type 2 diabetes in women managed for GDM during 2010 and 2011. Mothers who participated in the larger study were informed about the sub-study and invited to allow their children to participate in the sub-study. Written informed consent was obtained from the mothers for the sub-study. The following data were collected: anthropometric data at birth and pregnancy related information from the mothers’ hospital record, additional demographic, social and medical information by questionnaire from the mother and at the research center. In addition, the children were weighed and had their height measured using standardized methods. Anthropometry was standardized using WHO standards. Risk factors for overweight and obesity were tested using a BMI>1 Z-score cut-off, (as a binary variable) in a manual multivariate logistic regression model. Results: The sub-study recruited 176 participants; 78 boys (44.3%) and 98 girls (55.7%). The mean (SD) Z-scores for the children’s anthropometry at ages 5 to 6 years were 0.28 (1.40) for weight, 0.01 (1.07) for height and 0.37 (1.63) for BMI. The overall prevalence of macrosomia at birth (birth weight>4000 gm) was 12.3 % (95% CI 8.2-9.1). The overall prevalence of overweight in the 5 and 6-year-old children was 13.4% (95% CI 8.6-20.4), while the prevalence of obesity was 14.2% (95% CI 9.2-21.2). The combined prevalence of overweight and obesity was 27.6% (95% CI 20.6-35.9). The prevalence of macrosomia (P=0.53) or overweight/obesity proportions (P=0.37) at ages 5 to 6 years did not differ by gender. In multivariate logistic regression analysis, factors independently associated with the risk of overweight and obesity were: mothers’ oral glucose tolerance test 2-hour blood glucose level during pregnancy (AOR=2.06, 95% CI 1.14-3.74, P=0.02), birth weight (AOR=1.00, 95% CI 1.00-1.00, P=0.01), child’s age in years (AOR=0.03, 95% CI 0.002-0.29, P=0.004) and number of adults in the house (AOR=0.38, 95% CI 0.17-0.86, P=0.02). Conclusion: This is the first study to report the prevalence of overweight and obesity in children born from GDM complicated pregnancies, in the Western Cape, South Africa. The combined prevalence of overweight and obesity found in 5 and 6-year-old children exposed to GDM in the Western Cape is higher than overweight and obesity in children reported in other South African studies. This can imply a higher tendency towards overweight and obesity in children exposed to GDM which needs further exploration.

No description available.

No description available.

Despite many attempts to improve estimations based on ultrasound measures and volumes, the accurate prediction of birthweight hasremained elusive, particularly in relation to macrosomia.Now finally, after 7 years of dedicated research, we have managed to develop a rapid and precise, magnetic resonance imaging-basedtechnique, capable of accurately predicting birthweight, regardless of whether the estimations are performed, hours, days or even severalweeks prior to the actual birth.We believe that, once the already demonstrated advantages of the technique are confirmed in prospective, multi-centre studies, itwill become readily accessible for use in clinical practice and prove invaluable to clinicians as a reliable adjunct in many obstetricaldecision-making processes. / Doctorat en Sciences médicales (Médecine) / info:eu-repo/semantics/nonPublished

Orientador: Iracema de Mattos Paranhos Calderon / Resumo: Identificar fatores de risco para a macrossomia fetal na população de gestantes portadoras de diabete ou hiperglicemia diária. Método - Estudo retrospectivo, tipo caso-controle, incluindo 803 pares de mães e recém-nascidos desta população específica, distribuídos em dois grupos - macrossômicos (casos, n = 242) e não-macrossômicos (controles, n = 561). Foram comparadas variáveis relativas à idade, paridade, peso e índice de massa corporal (IMC), ganho de peso (GP), antecedentes de diabete, hipertensão arterial e tabagismo, tipo e classificação do diabete e indicadores do controle glicêmico no terceiro trimestre. As médias foram avaliadas pelo teste F e as variáveis categorizadas foram submetidas à análise univariada, utilizando-se o teste do qui-quadrado (c²). Os resultados significativos foram incluídos no modelo de regressão múltipla, para identificação do risco independente de macrossomia, considerando-se OR, IC95% e valor de p. Para todas as análises foi estabelecido o limite de significância estatística de 5% (p < 0,05). Resultados - Observou-se associação significativa entre macrossomia e GP > 16kg, IMC = 25kg/m2, antecedentes pessoais, obstétricos e, especificamente, o de macrossomia, classificação nos grupos de Rudge (IB e IIA + IIB), média glicêmica (MG) ³120mg/dL e média de glicemia pósprandial (MPP) ³ 130mg/dL no terceiro trimestre. Na análise de regressão múltipla, o GP > 16kg (OR = 1,79; IC95% = 1,23 ¾ 1,60), o IMC = 25kg/m² (OR = 1,83; IC95% = 1,27 ¾ 2,64), o antecedente pessoal de diabete (OR = 1,56; IC95% = 1,05 ¾ 2,31) e de macrossomia (OR = 2,37; IC95% = 1,60 ¾ 3,50) e a MG ³120mg/dL no terceiro trimestre (OR = 1,78; IC95% = 1,13 ¾ 2,80) confirmaram risco independente para macrossomia nestas gestações de risco. Conclusão - O GP > 16Kg, o IMC ³ 25Kg/m2, a MG ³ 120mg/dL no terceiro trimestre e a presença... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: To identify risk factors for fetal macrosomia in pregnant women having diabetes or daily hyperglycemia. Method - Retrospective study, control-case, including 803 pairs of mothers and newborns belonging to this specific population, distributed in two groups- macrosomic (cases, n = 242) and non-macrosomic (controls, n = 561). Variables related to age, parity, weight and body mass index (BMI), weight gain (WG), diabetes history, high blood pressure and tabagism, diabetes type and classification and glycemic control indicators in the third trimester were compared. The means were evaluated by the F test and the categorized variables were submitted to univariate analysis using the chi square test (c²). The significative results were included in the multiple regression model for the identification of macrosomia independent risk considering OR, 95% CI and p value. The statistical significance limit of 5% was established for all the analysis. Results - There was significative association between macrosomia and WG > 16kg, BMI = 25kg/m², personal, obstetric and macrosomic history, classification in the Rudge groups (IB and IIA + IIB), glycemic mean (GM) = 120mg/dL and postprandial glycemic mean (PPGM) = 130mg/dL in the third trimester. In the multiple regression analysis, the WG > 16kg (OR= 1,79; 95%CI= 1,23 - 1,60), the BMI ³ 25kg/m² (OR = 1,83; 95% CI = 1,27 - 2,64), the diabetes personal history (OR = 1,56; 95%CI = 1,05 - 2,31), and of macrossomia (OR = 2,37; 95%CI= 1,60- 3,50) and the GM ³ 120mg/dL in the third trimester (OR = 1,78; 95%= 1,13 - 2,80) confirmed independent risk for macrossomia in these risk pregnancies. Conclusion - The WG > 16kg, the BMI ³ 25kg/m², the GM = 120mg/dL in the third trimester and macrosomia and diabetes personal history were identified as risk factors for fetal macrosomia in pregnant women having diabetes or daily hyperglycemia. / Mestre

O Diabetes melito gestacional (DMG) está relacionado ao crescimento fetal exagerado. Entender a influência do controle glicêmico no padrão do crescimento fetal auxilia na identificação dos fetos com maior risco de desvios da normalidade. Objetivo: comparar o crescimento fetal em pacientes com DMG segundo o controle glicêmico. Método: estudo retrospectivo com 89 gestantes da Clínica Obstétrica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo no período de maio de 2005 a junho de 2011. Foram incluídas apenas pacientes com gestações únicas e com DMG diagnosticado pelo teste de tolerância oral à glicose de 100 gramas ou 75 gramas, sem doenças maternas que interferem no ganho de peso fetal, sem malformações fetais ou tabagismo. Todas as gestantes realizaram retornos semanais no pré-natal especializado, dieta para diabetes, controle glicêmico diário e uso de insulina quando necessário. Foi introduzida insulina quando 30% ou mais das glicemias capilares aferidas em uma semana eram superiores a: jejum> 95 mg/dl, 1hora pós-prandial> 140 mg/dl ou 2 horas pós-prandial> 120 mg/dl. As gestantes foram divididas para análise dos dados em dois grupos: se apresentassem menos de 30% de hiperglicemias em todas as glicemias capilares aferidas eram alocadas no grupo 1 (n= 65), e caso contrário no grupo 2 (n=24). Elas realizaram três ultrassonografias (USG): USG 0 (entre 18 a 24 semanas), USG 1 (início do tratamento do DMG) e USG 2 (final do tratamento). Foram analisadas as médias dos percentis do peso e da circunferência abdominal fetal para avaliação do padrão do crescimento fetal, e o ganho de peso fetal entre os USG. Resultados: Não houve diferenças quanto à: idade materna e índice de massa corpórea pré-gestacional; ganho de peso materno no pré-natal; idade gestacional do diagnóstico do DMG e do início do tratamento; idade gestacional da realização das USG. As médias glicêmicas foram de 98,7 mg/dl no grupo 1 e de 111,9 mg/dl no grupo 2 (p<0,001). O uso de insulina foi de 16,9% vs. 87,5%; p<0, 001 nos grupos 1 e 2, respectivamente. O valor da hemoglobina glicada no diagnóstico de DMG foi maior no grupo 2 (5,52% vs. 5,93%; p<0,001). Os percentis do peso fetal foram semelhantes entre os grupos no USG 0 e no USG 1, porém significativamente maiores no grupo 2 no USG 2 (p=0,02). Os percentis da circunferência abdominal fetal foram significativamente maiores no grupo 2 no USG 1 e USG 2. O grupo 2 apresentou um maior ganho de peso fetal (27,53 gramas/dia vs. 33,43gramas/dia; p=0,001) e um maior peso ao nascer (3247g. vs. 3499g.; p=0,025). Conclusões: O controle glicêmico influenciou no peso fetal, as gestantes que apresentaram mais de 30% de hiperglicemia durante o pré-natal apresentaram maior velocidade de ganho de peso fetal durante o tratamento e recém-nascidos com maior peso ao nascer. O percentil da circunferência abdominal fetal parece modificar antes que o percentil do peso fetal e seria um marcador mais sensível de alterações no potencial de crescimento fetal. / Gestational diabetes (GDM) is related to overgrowth fetal. Objective: To evaluate fetal growth in patients with gestational diabetes (GD) according to glycemic control. Methods: Eighty-nine pregnant women seen at the Obstetric Clinic of the University Hospital, University of São Paulo School of Medicine, between May 2005 and June 2011 were studied retrospectively. The study included non-smoking women with singleton pregnancies and GD diagnosed by the 100- or 75-g oral glucose tolerance test. The patients had no maternal disease interfering with fetal weight gain and there were no fetal malformations. All women attended weekly specialized prenatal care, consumed a diabetes diet, performed daily glycemic control, and used insulin when necessary. Insulin was introduced when >=30% of the capillary glucose measurements obtained in one week were >95 mg/dl (fasting), >140 mg/dl (1 h postprandial), or >120 mg/dl (2 h postprandial). The women were divided into two groups according to the frequency of hyperglycemic episodes in all capillary glucose measurements obtained during treatment: group 1 (n = 65, <=30%), and group 2 (n = 24, >30%). Ultrasound (US) was performed at three time points for the comparison of mean fetal weight and abdominal circumference percentiles and fetal weight gain (g/day): US0 (18 to 24 weeks), US1 (at the beginning of treatment of GD), and US2 (at the end of treatment) Results: The two groups did not differ in terms of maternal age, pregestational BMI, prenatal maternal weight gain, gestational age at the diagnosis of GD, time of onset of treatment, or gestational age at US. Mean glycemia was 98.7 mg/dl in group 1 and 111.9 mg/dl in group 2 (p<0.001). Insulin was used by 16.9% of the patients of group 1 vs. 87.5% of group 2 (p<0.001). HbA1c at diagnosis of GD was higher in group 2 (5.52% vs. 5.93%; p<0.001). Fetal weight percentiles were similar in the two groups at US0 and US1, but significantly higher in group 2 at US2 (p=0.02). Abdominal circumference percentiles were significantly higher in group 2 at US1 and US2. Fetal weight gain (27.5 vs. 33.4 g/day; p=0.001) and birthweight (3247 vs. 3499 g; p=0.025) were higher in group 2. Conclusions: The pattern of fetal growth in patients with GD varies according to glycemic control. The fetal growth velocity and newborn birthweight were higher in women who presented >30% of hyperglycemic episodes during treatment of GD. The abdominal circumference percentile seems to change before the weight percentile and would be a more sensitive marker of altered fetal growth.

O Diabetes melito gestacional (DMG) está relacionado ao crescimento fetal exagerado. Entender a influência do controle glicêmico no padrão do crescimento fetal auxilia na identificação dos fetos com maior risco de desvios da normalidade. Objetivo: comparar o crescimento fetal em pacientes com DMG segundo o controle glicêmico. Método: estudo retrospectivo com 89 gestantes da Clínica Obstétrica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo no período de maio de 2005 a junho de 2011. Foram incluídas apenas pacientes com gestações únicas e com DMG diagnosticado pelo teste de tolerância oral à glicose de 100 gramas ou 75 gramas, sem doenças maternas que interferem no ganho de peso fetal, sem malformações fetais ou tabagismo. Todas as gestantes realizaram retornos semanais no pré-natal especializado, dieta para diabetes, controle glicêmico diário e uso de insulina quando necessário. Foi introduzida insulina quando 30% ou mais das glicemias capilares aferidas em uma semana eram superiores a: jejum> 95 mg/dl, 1hora pós-prandial> 140 mg/dl ou 2 horas pós-prandial> 120 mg/dl. As gestantes foram divididas para análise dos dados em dois grupos: se apresentassem menos de 30% de hiperglicemias em todas as glicemias capilares aferidas eram alocadas no grupo 1 (n= 65), e caso contrário no grupo 2 (n=24). Elas realizaram três ultrassonografias (USG): USG 0 (entre 18 a 24 semanas), USG 1 (início do tratamento do DMG) e USG 2 (final do tratamento). Foram analisadas as médias dos percentis do peso e da circunferência abdominal fetal para avaliação do padrão do crescimento fetal, e o ganho de peso fetal entre os USG. Resultados: Não houve diferenças quanto à: idade materna e índice de massa corpórea pré-gestacional; ganho de peso materno no pré-natal; idade gestacional do diagnóstico do DMG e do início do tratamento; idade gestacional da realização das USG. As médias glicêmicas foram de 98,7 mg/dl no grupo 1 e de 111,9 mg/dl no grupo 2 (p<0,001). O uso de insulina foi de 16,9% vs. 87,5%; p<0, 001 nos grupos 1 e 2, respectivamente. O valor da hemoglobina glicada no diagnóstico de DMG foi maior no grupo 2 (5,52% vs. 5,93%; p<0,001). Os percentis do peso fetal foram semelhantes entre os grupos no USG 0 e no USG 1, porém significativamente maiores no grupo 2 no USG 2 (p=0,02). Os percentis da circunferência abdominal fetal foram significativamente maiores no grupo 2 no USG 1 e USG 2. O grupo 2 apresentou um maior ganho de peso fetal (27,53 gramas/dia vs. 33,43gramas/dia; p=0,001) e um maior peso ao nascer (3247g. vs. 3499g.; p=0,025). Conclusões: O controle glicêmico influenciou no peso fetal, as gestantes que apresentaram mais de 30% de hiperglicemia durante o pré-natal apresentaram maior velocidade de ganho de peso fetal durante o tratamento e recém-nascidos com maior peso ao nascer. O percentil da circunferência abdominal fetal parece modificar antes que o percentil do peso fetal e seria um marcador mais sensível de alterações no potencial de crescimento fetal. / Gestational diabetes (GDM) is related to overgrowth fetal. Objective: To evaluate fetal growth in patients with gestational diabetes (GD) according to glycemic control. Methods: Eighty-nine pregnant women seen at the Obstetric Clinic of the University Hospital, University of São Paulo School of Medicine, between May 2005 and June 2011 were studied retrospectively. The study included non-smoking women with singleton pregnancies and GD diagnosed by the 100- or 75-g oral glucose tolerance test. The patients had no maternal disease interfering with fetal weight gain and there were no fetal malformations. All women attended weekly specialized prenatal care, consumed a diabetes diet, performed daily glycemic control, and used insulin when necessary. Insulin was introduced when >=30% of the capillary glucose measurements obtained in one week were >95 mg/dl (fasting), >140 mg/dl (1 h postprandial), or >120 mg/dl (2 h postprandial). The women were divided into two groups according to the frequency of hyperglycemic episodes in all capillary glucose measurements obtained during treatment: group 1 (n = 65, <=30%), and group 2 (n = 24, >30%). Ultrasound (US) was performed at three time points for the comparison of mean fetal weight and abdominal circumference percentiles and fetal weight gain (g/day): US0 (18 to 24 weeks), US1 (at the beginning of treatment of GD), and US2 (at the end of treatment) Results: The two groups did not differ in terms of maternal age, pregestational BMI, prenatal maternal weight gain, gestational age at the diagnosis of GD, time of onset of treatment, or gestational age at US. Mean glycemia was 98.7 mg/dl in group 1 and 111.9 mg/dl in group 2 (p<0.001). Insulin was used by 16.9% of the patients of group 1 vs. 87.5% of group 2 (p<0.001). HbA1c at diagnosis of GD was higher in group 2 (5.52% vs. 5.93%; p<0.001). Fetal weight percentiles were similar in the two groups at US0 and US1, but significantly higher in group 2 at US2 (p=0.02). Abdominal circumference percentiles were significantly higher in group 2 at US1 and US2. Fetal weight gain (27.5 vs. 33.4 g/day; p=0.001) and birthweight (3247 vs. 3499 g; p=0.025) were higher in group 2. Conclusions: The pattern of fetal growth in patients with GD varies according to glycemic control. The fetal growth velocity and newborn birthweight were higher in women who presented >30% of hyperglycemic episodes during treatment of GD. The abdominal circumference percentile seems to change before the weight percentile and would be a more sensitive marker of altered fetal growth.

<p>The appropriateness of universal screening for gestational diabetes mellitus (GDM) has been strongly questioned, since it does not satisfy ethical principles for screening. </p><p> The aims of these studies were to determine the prevalence of GDM, expressed in terms of impaired glucose tolerance (IGT) and diabetes mellitus (DM), to evaluate different screening models using traditional anamnestic risk factors and repeated random B-glucose, to determine whether GDM increases risks for maternal complications such as preeclampsia, and to determine whether IGT during pregnancy, if left untreated, is associated with increased maternal or neonatal morbidity. </p><p> Of 4,918 pregnant non-diabetic women attending maternal health care, 73.5% agreed to have a 75 g oral glucose tolerance test (OGTT). GDM was diagnosed in 1.7%, IGT in 1.3% and DM in 0.4%. Traditional risk factor criteria were fulfilled by 15.8%. Prior GDM and a prior macrosomic infant showed the highest association with GDM. No selective or two-step universal screening model would have detected all cases of GDM. A constructed model comprising prior GDM, a prior LGA/macrosomic infant, or a cut-off random B-glucose level of 8 mmol/l as an indication for OGTT reduced the need for OGTT to 7.3% compared to the selective screening model with traditional risk factors. Such a universal two-step screening model had 100% sensitivity for DM, and 44.7% sensitivity for IGT.</p><p> The Swedish Medical Birth Register was used to evaluate GDM as risk factor for preeclampsia. GDM occurred in 0.8% and preeclampsia in 2.9% of 430,852 singleton pregnancies. There is an independent and significant association between GDM and preeclampsia. Obesity is a major confounding factor, but cannot explain the total excess risk. </p><p> In a prospective population-based case-control study 213 women with untreated IGT during pregnancy were identified. For each case, four controls were recruited from the same delivery department. The analyses confirmed that maternal and fetal morbidity were increased in the cases in terms of cesarean section rate, pre-term delivery, Erb’s palsy and admission to NICU. There was a marked, independent increase in the proportion of LGA infants (OR 7.3; 95% CI 4.1-12.7). To determine whether treatment has an effect when IGT is diagnosed during pregnancy, a randomized study is required.</p>

The appropriateness of universal screening for gestational diabetes mellitus (GDM) has been strongly questioned, since it does not satisfy ethical principles for screening. The aims of these studies were to determine the prevalence of GDM, expressed in terms of impaired glucose tolerance (IGT) and diabetes mellitus (DM), to evaluate different screening models using traditional anamnestic risk factors and repeated random B-glucose, to determine whether GDM increases risks for maternal complications such as preeclampsia, and to determine whether IGT during pregnancy, if left untreated, is associated with increased maternal or neonatal morbidity. Of 4,918 pregnant non-diabetic women attending maternal health care, 73.5% agreed to have a 75 g oral glucose tolerance test (OGTT). GDM was diagnosed in 1.7%, IGT in 1.3% and DM in 0.4%. Traditional risk factor criteria were fulfilled by 15.8%. Prior GDM and a prior macrosomic infant showed the highest association with GDM. No selective or two-step universal screening model would have detected all cases of GDM. A constructed model comprising prior GDM, a prior LGA/macrosomic infant, or a cut-off random B-glucose level of 8 mmol/l as an indication for OGTT reduced the need for OGTT to 7.3% compared to the selective screening model with traditional risk factors. Such a universal two-step screening model had 100% sensitivity for DM, and 44.7% sensitivity for IGT. The Swedish Medical Birth Register was used to evaluate GDM as risk factor for preeclampsia. GDM occurred in 0.8% and preeclampsia in 2.9% of 430,852 singleton pregnancies. There is an independent and significant association between GDM and preeclampsia. Obesity is a major confounding factor, but cannot explain the total excess risk. In a prospective population-based case-control study 213 women with untreated IGT during pregnancy were identified. For each case, four controls were recruited from the same delivery department. The analyses confirmed that maternal and fetal morbidity were increased in the cases in terms of cesarean section rate, pre-term delivery, Erb’s palsy and admission to NICU. There was a marked, independent increase in the proportion of LGA infants (OR 7.3; 95% CI 4.1-12.7). To determine whether treatment has an effect when IGT is diagnosed during pregnancy, a randomized study is required.